{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:22:11Z","timestamp":1793892131737,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prognostic scores are an important tool in medical statistics. In chronic myeloid leukaemia (CML), prognostic models have existed for many years, enabling the classification of patients into groups that can be clearly differentiated in terms of their prognosis. However, over time, the focus of these models has shifted from solely survival outcomes to a broader range of diverse endpoints. This review explores the development and applications of these scores, offering recommendations for their use, and looks ahead to potential future advancements in the field. As the landscape of CML treatment evolves with newer therapeutic options, it is crucial to adapt prognostic models to reflect not only survival rates but also other important clinical milestones such as molecular remission, progression-free survival, and CML-related survival. The continued refinement of these tools, alongside international validation efforts, will be essential in providing clinicians with more accurate and individualized patient prognostication, ultimately improving therapeutic decision-making and patient outcomes.<\/jats:p>","DOI":"10.1038\/s41375-025-02606-6","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:12:32Z","timestamp":1744715552000},"page":"1046-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic scoring systems in chronic myeloid leukaemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7127","authenticated-orcid":false,"given":"Michael","family":"Lauseker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-5390","authenticated-orcid":false,"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8948-0690","authenticated-orcid":false,"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2606_CR2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/JTO.0b013e318292bdcd","volume":"8","author":"L Simms","year":"2013","unstructured":"Simms L, Barraclough H, Govindan R. Biostatistics Primer: What a Clinician Ought to Know\u2014Prognostic and Predictive Factors. J Thorac Oncol. 2013;8:808\u201313.","journal-title":"J Thorac Oncol"},{"key":"2606_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2016.142877","volume":"101","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016;101:657\u20139.","journal-title":"Haematologica"},{"key":"2606_CR4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2606_CR5","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"2606_CR6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2023-182792","volume":"142","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Br\u00fcmmendorf TH, et al. Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial. Blood. 2023;142:446.","journal-title":"Blood"},{"key":"2606_CR7","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J"},{"key":"2606_CR8","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"2606_CR9","doi-asserted-by":"crossref","unstructured":"Chen EY, Dahlen T, Stenke L, Bjorkholm M, Hao S, Dickman PW, et al. Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia. Eur J Haematol. 2024;114:334\u201342.","DOI":"10.1111\/ejh.14328"},{"key":"2606_CR10","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186\u201393.","journal-title":"Lancet Haematol"},{"key":"2606_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","volume":"2019","author":"H Malhotra","year":"2019","unstructured":"Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology. 2019;2019:433\u201342.","journal-title":"Hematology"},{"key":"2606_CR12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2606_CR13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2606_CR14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25:1433\u20138.","journal-title":"Leukemia"},{"key":"2606_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"G Smith","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191:171\u201393.","journal-title":"Br J Haematol"},{"key":"2606_CR16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"J Sokal","year":"1984","unstructured":"Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"2606_CR17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"2606_CR18","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon F, et al. Prognostic factors. In: Carella AM, Daley G, Eaves C, Goldman J, Hehlmann R, editors. Chronic myeloid leukemia\u2014biology and treatment. London: Martin Dunitz; 2001. p. 205\u201323."},{"key":"2606_CR19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"2606_CR20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.leukres.2014.06.006","volume":"38","author":"Z Tao","year":"2014","unstructured":"Tao Z, Liu B, Zhao Y, Wang Y, Zhang R, Han M, et al. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib. Leuk Res. 2014;38:1030\u20135.","journal-title":"Leuk Res"},{"key":"2606_CR21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","volume":"31","author":"VS Hoffmann","year":"2017","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31:593\u2013601.","journal-title":"Leukemia"},{"key":"2606_CR22","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27:2016\u201322.","journal-title":"Leukemia"},{"key":"2606_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-013-1974-z","volume":"93","author":"M Bonifacio","year":"2014","unstructured":"Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M, Gruppo TrivenetoLMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. Ann Hematol. 2014;93:163\u20134.","journal-title":"Ann Hematol"},{"key":"2606_CR24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia"},{"key":"2606_CR25","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1002\/cam4.3516","volume":"9","author":"E Sato","year":"2020","unstructured":"Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020;9:8931\u20139.","journal-title":"Cancer Med"},{"key":"2606_CR26","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-018-0136-7","volume":"32","author":"IGP Geelen","year":"2018","unstructured":"Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients. Leukemia. 2018;32:2299\u2013303.","journal-title":"Leukemia"},{"key":"2606_CR27","first-page":"E661","volume":"92","author":"M Molica","year":"2017","unstructured":"Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, et al. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol. 2017;92:E661\u2013E4.","journal-title":"Am J Hematol"},{"key":"2606_CR28","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2147\/CMAR.S237467","volume":"12","author":"X Yang","year":"2020","unstructured":"Yang X, Bai Y, Shi M, Zhang W, Niu J, Wu C, et al. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study. Cancer Manag Res. 2020;12:1293\u2013301.","journal-title":"Cancer Manag Res"},{"key":"2606_CR29","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.25628","volume":"94","author":"M Lauseker","year":"2019","unstructured":"Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Stromberg U, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019;94:1236\u201343.","journal-title":"Am J Hematol"},{"key":"2606_CR30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood-2023-173810","volume":"142","author":"F Millot","year":"2023","unstructured":"Millot F, De Keizer J, Metzler M, Suttorp M, Sedlacek P, Luesink M, et al. Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML. Blood. 2023;142:448.","journal-title":"Blood"},{"key":"2606_CR31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","volume":"102","author":"F Millot","year":"2017","unstructured":"Millot F, Guilhot J, Suttorp M, Gunes AM, Sedlacek P, De Bont E, et al. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica. 2017;102:1704\u20138.","journal-title":"Haematologica"},{"key":"2606_CR32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","volume":"94","author":"D Gurrea Salas","year":"2015","unstructured":"Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?. Ann Hematol. 2015;94:1363\u201371.","journal-title":"Ann Hematol"},{"key":"2606_CR33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:1336\u201342.","journal-title":"Leukemia"},{"key":"2606_CR34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/s41375-023-01875-3","volume":"37","author":"X Zhang","year":"2023","unstructured":"Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023;37:1166\u20139.","journal-title":"Leukemia"},{"key":"2606_CR35","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1080\/10428194.2023.2255804","volume":"64","author":"C Ielo","year":"2023","unstructured":"Ielo C, Scalzulli E, Carmosino I, Pepe S, Bisegna ML, Martelli M, et al. Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice. Leuk Lymphoma. 2023;64:2324\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2606_CR36","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41375-022-01616-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Li ZY, Zhang MY, Huang XJ, Jiang Q. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:2042\u20139.","journal-title":"Leukemia"},{"key":"2606_CR37","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41375-023-01982-1","volume":"37","author":"F Qi","year":"2023","unstructured":"Qi F, Zhang X, Gale RP, Liu B, Huang J, Huang X, et al. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy. Leukemia. 2023;37:1922\u20134.","journal-title":"Leukemia"},{"key":"2606_CR38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2024024761","volume":"144","author":"X Zhang","year":"2024","unstructured":"Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale RP, et al. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Blood. 2024;144:1951\u201361.","journal-title":"Blood"},{"key":"2606_CR39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transpl. 2015;21:1479\u201387.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2606_CR40","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2606_CR41","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"2606_CR42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905\u201313.","journal-title":"Blood"},{"key":"2606_CR43","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"},{"key":"2606_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2606_CR45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087\u201392.","journal-title":"Lancet"},{"key":"2606_CR46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","volume":"125","author":"JR Passweg","year":"2004","unstructured":"Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004;125:613\u201320.","journal-title":"Br J Haematol"},{"key":"2606_CR47","first-page":"232","volume":"90","author":"CA De Souza","year":"2005","unstructured":"De Souza CA, Vigorito AC, Ruiz MA, Nucci M, Dulley FL, Funcke V, et al. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. Haematologica. 2005;90:232\u20137.","journal-title":"Haematologica"},{"key":"2606_CR48","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513\u201321.","journal-title":"Haematologica"},{"key":"2606_CR49","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","volume":"34","author":"M Pfirrmann","year":"2020","unstructured":"Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138\u201349.","journal-title":"Leukemia"},{"key":"2606_CR50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia. 2022;36:482\u201391.","journal-title":"Leukemia"},{"key":"2606_CR51","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s41375-021-01292-4","volume":"35","author":"M Breccia","year":"2021","unstructured":"Breccia M, Pregno P, Castagnetti F, Bonifacio M, Tiribelli M, Gozzini A, et al. Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. Leukemia. 2021;35:1814\u20136.","journal-title":"Leukemia"},{"key":"2606_CR52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12185-024-03758-4","volume":"120","author":"N Iriyama","year":"2024","unstructured":"Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. Int J Hematol. 2024;120:60\u201370.","journal-title":"Int J Hematol"},{"key":"2606_CR53","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Lauseker M, Hoffmann V, Hasford J. Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-specific Death. In: Hehlmann R, editor. Chronic Myeloid Leukemia. 2nd ed. Switzerland: Springer; 2021. p. 119\u201343.","DOI":"10.1007\/978-3-030-71913-5_9"},{"key":"2606_CR54","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37:2150\u201367.","journal-title":"Leukemia"},{"key":"2606_CR55","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2606_CR56","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.2024026119","volume":"144","author":"G Saglio","year":"2024","unstructured":"Saglio G. Importance of predicting CML therapy failure. Blood. 2024;144:1852\u20133.","journal-title":"Blood"},{"key":"2606_CR57","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34:2074\u201386.","journal-title":"Leukemia"},{"key":"2606_CR58","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"2606_CR59","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"2606_CR60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. J Clin Oncol. 2012;30:232\u20138.","journal-title":"J Clin Oncol"},{"key":"2606_CR61","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096\u2013102.","journal-title":"Leukemia"},{"key":"2606_CR62","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","volume":"37","author":"M Lauseker","year":"2023","unstructured":"Lauseker M, Hehlmann R, Hochhaus A. Saussele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023;37:2231\u20136.","journal-title":"Leukemia"},{"key":"2606_CR63","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ije\/dyab047","volume":"50","author":"ER Andrinopoulou","year":"2021","unstructured":"Andrinopoulou ER, Harhay MO, Ratcliffe SJ, Rizopoulos D. Reflection on modern methods: Dynamic prediction using joint models of longitudinal and time-to-event data. Int J Epidemiol. 2021;50:1731\u201343.","journal-title":"Int J Epidemiol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02606-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:46:50Z","timestamp":1746532010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02606-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}